Browse > Article
http://dx.doi.org/10.24304/kjcp.2020.30.1.59

A Case Report of Cyanopsia after Taking Sildenafil  

Lee, Chan Hee (College of Pharmacy, Gachon University)
Yoon, Joong Sik (Regional Pharmacovigilance Center, Korean Pharmaceutical Association)
Ji, Eunhee (College of Pharmacy, Gachon University)
Publication Information
Korean Journal of Clinical Pharmacy / v.30, no.1, 2020 , pp. 59-64 More about this Journal
Abstract
The emergence of phosphodiesterase (PDE) 5 inhibitors gave rise to the solution for erectile dysfunction, starting with the development of sildenafil. Although their efficacy in treating erectile dysfunction has been shown, the side effects of PDE5 inhibitors, especially sildenafil, must be taken into consideration. A 64-year-old man received 100 mg of sildenafil and experienced blue vision in both eyes; however, after a day or so, his symptoms improved. The symptoms disappeared when he stopped administering sildenafil, but reappeared when the medication was re-administered. Therefore, he discontinued sildenafil treatment and was prescribed udenafil instead. After that, visual adverse events no longer occurred. Causality assessment showed that in this case, sildenafil-induced cyanopsia was "certain" under the World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria and Korean causality assessment algorithm (Ver.2), and was "probable" according to the Naranjo scale. In addition, sildenafil also led to abnormal visual reactions in other cases. Sildenafil can also inhibit PDE6, which is present in retinal cells, unlike other PDE5 inhibitors. Thus, visual adverse reactions, such as blue vision, are the unique results of sildenafil, and other PDE5 inhibitors may be used to prevent them.
Keywords
Sildenafil; cyanopsia; phosphodiesterase (PDE); adverse event; causality assessment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54-61.   DOI
2 Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49(5):806-15.   DOI
3 Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors In the management of erectile dysfunction. P T 2013;38(7):407-19.
4 Ministry of Food and Drug Safety Integrated Medicine Information System. $VIAGRA^{(R)}$ Tablets 50 mg/ 100 mg (sildenafil citrate) 2014. Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200410082. Accessed August 16, 2019.
5 Ministry of Food and Drug Safety Integrated Medicine Information System. Cialis 10 mg (tadalafil) 2017. Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200307768. Accessed August 16, 2019.
6 Ministry of Food and Drug Safety Integrated Medicine Information System. Zydena 100 mg (udenafil). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200500258. Accessed August 16, 2019.
7 World Health Organization (WHO) - Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Available from https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed Jun 17, 2019.
8 Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.   DOI
9 Guler S, Gokcek I, Guven I, et al. Blue vision and sinus tachycardia: sildenafil citrate overdose. J Acad Emerg Med 2015;6:87-9.
10 Hong KS, Park BJ, Sin SG. Development of a Korean algorithm for causality assessment of adverse drug reactions. J Korean Soc Clin Pharmacol Ther 2002;10:129-42.   DOI
11 Li Y-Y, Yu Y-J, Liu X-P, et al. Visual impairment with possible macular changes after a high dose of sildenafil in a healthy young woman. Int J Ophthalmol 2018;11(2):340-2.   DOI
12 Yanoga F, Gentile RC, Chui TYP, et al. Sildenafil citrate induced retinal toxicity-electroetinogram, optical coherence tomography, and adaptive optics findings. Retin Cases Brief Rep 2018;12 (Suppl 1):S33-S40.   DOI
13 Lue TF. Erectile dysfunction. N Engl J Med 2000;342(24):1802-13.   DOI
14 Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997;157(1):320-4.   DOI
15 Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274(20):13729-32.   DOI
16 Ignarro LJ, Bush PA, Buga GM, et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170(2):843-50.   DOI
17 Laties A, Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002;21(5):485-506.   DOI
18 Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8(2):47-52.
19 Miller WH, Nicol GD. Evidence that cyclic GMP regulates membrane potential in rod photoreceptors. Nature 1979;280(5717):64-6.   DOI
20 Ames A, 3rd, Barad M. Metabolic flux of cyclic GMP and phototransduction in rabbit retina. J Physiol 1988;406:163-79.   DOI
21 Pugh EN, Jr., Lamb TD. Cyclic GMP and calcium: the internal messengers of excitation and adaptation in vertebrate photoreceptors. Vision Res 1990;30(12):1923-48.   DOI
22 Lagnado L, Baylor D. Signal flow in visual transduction. Neuron 1992;8(6):995-1002.   DOI
23 Ebrey T, Koutalos Y. Vertebrate photoreceptors. Prog Retin Eye Res 2001;20(1):49-94.   DOI
24 Lolley RN, Farber DB, Rayborn ME, et al. Cyclic GMP accumulation causes degeneration of photoreceptor cells: simulation of an inherited disease. Science 1977;196(4290):664-6.   DOI
25 Ulshafer RJ, Garcia CA, Hollyfield JG. Sensitivity of photoreceptors to elevated levels of cGMP in the human retina. Optom Vis Sci 1980;19(10):1236-41.
26 Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83(5):3-12.   DOI
27 Nivison-Smith L, Zhu Y, Whatham A, et al. Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. Exp Eye Res 2014;128:43-56.   DOI
28 Tsang SH, Gouras P, Yamashita CK, et al. Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase. Science 1996;272(5264):1026-9.   DOI
29 Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res 2004;16(1):S28-S33.   DOI
30 Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159(6):2164-71.   DOI
31 Wallis RM. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nihon Yakurigaku Zasshi 1999;114 Suppl 1:22-6.   DOI
32 Taylor J, Baldo OB, Storey A, et al. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009;103(10):1392-5.   DOI
33 Pfizer Labs. Full prescribing information for VIAGRA 2017. Available from https://www.pfizermedicalinformation.com/en-us/viagra/adverse-reactions. Accessed August 26, 2019.
34 Kotera J, Mochida H, Inoue H, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol 2012;188(2):668-74.   DOI
35 Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56(6):453-9.